(3-Oxo-1,3-dihydro-isobenzofuran-1-yl)-triphenyl-phosphonium; chloride | 38152-32-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-Oxo-1,3-dihydro-isobenzofuran-1-yl)-triphenyl-phosphonium; chloride
• 英文别名: (3-oxo-1H-2-benzofuran-1-yl)-triphenylphosphanium;chloride
• CAS: 38152-32-8
• 化学式: C₂₆H₂₀O₂P*Cl
• 分子量: 430.87
• InChiKey: MFTUDGQVGLBVEO-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.85
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Phthalazine derivatives for treating inflammatory diseases
  申请人：——

  公开号：US20030013718A1

  公开（公告）日：2003-01-16

  The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, 1 wherein r is 0 to 2, n is 0 to 3 R 1 and R 2 a) are independently in each case a lower alkyl; b) together form a bridge of subformula I*, 2 wherein the bond is achieved via the two terminal C atoms and m is 0 to 4, or c) together form a bridge of subformula I**, 3 wherein one or two of the ring members T 1 , T 2 , T 3 and T 4 are nitrogen, and the others are in each case CH, and the bond is achieved via atoms T 1 and T 4 ; G is —C(═O)—, —CHF—, —CF 2 —, lower alkylene, C 2 -C 6 alkenylene, lower alkylene or C 3 -C 6 alkenylene substituted by acyloxy or hydroxy, —CH 2 —O—, —CH 2 —S—, —CH 2 —NH—, —CH 2 —O—CH 2 —, —CH 2 —S—CH 2 —, —CH 2 —NH—CH 2 —, oxa (—O—), thia (—S—), imino (—NH—), —CH 2 —O—CH 2 —, —CH 2 —S—CH 2 — or —CH 2 —NH—CH 2 —; A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N; Q is lower alkyl, lower alkoxy or halogen; R a and R a ′ are each independently H or lower alkyl; X is imino, oxa, or thia; Y is hydrogen, aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and Z is mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl lower alkylthio, alkylphenylthio, phenylsulfinyl, phenyl-lower alkylsulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, alkylphenylsulfonyl, or (alternatively or, in a broader aspect of the invention, in addition) selected from the group consisting of ureido, halo-lower alkylthio, halo-lower alkansulfonyl, pyrazolyl, lower-alkyl pyrazolyl and C 2 -C 7 alkenyl; wherein—if more than 1 radical Z (m≧2) is present—the substituents Z are selected independently from each other; and wherein the bonds characterized in subformula I* by a wavy line are either single or double bonds; or an N-oxide of said compound, wherein 1 or more N atoms carry an oxygen atom; or a pharmaceutically acceptable salt thereof; as well as to new phthalazine derivatives; processes for the preparation thereof; the application thereof in a process for the treatment of the human or animal body; the use thereof for the treatment of a disease, especially a disease caused by ocular neovascularisation, such as age-related macula degeneration or diabetic retinopathy, or other diseases that respond to the inhibition of tyrosine kinases, such as a proliferative disease; a method for the treatment of such disease in mammals; and the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment especially of a disease as mentioned above.

  该发明涉及治疗炎症性疾病，特别是炎症性风湿性或风湿性疾病，以及/或疼痛的方法，该方法使用公式I,1中VEGF受体酪氨酸激酶活性抑制剂，其中r为0至2，n为0至3，R1和R2a）各自独立地为较低的烷基；b）共同形成亚式I*，2的桥，其中通过两个末端C原子实现键合，m为0至4；或c）共同形成亚式I**，3的桥，其中环成员T1、T2、T3和T4中的一个或两个是氮，其他各自为CH，通过原子T1和T4实现键合；G为—C(═O)—、—CHF—、—CF2—、较低烷基、C2-C6烯基、被乙酰氧基或羟基取代的较低烷基或C3-C6烯基、—CH2—O—、— —S—、— —NH—、— —O— —、— —S— —、— —NH— —、氧杂环（—O—）、硫杂环（—S—）、亚胺（—NH—）、— —O— —、— —S— —或— —NH— —；A、B、D、E和T各自独立地为N或CH，但至少一个且不超过三个为N；Q为较低烷基、较低烷氧基或卤素；Ra和Ra′各自独立地为H或较低烷基；X为亚胺、氧杂环或硫杂环；Y为氢、芳基、杂环芳基或未取代或取代的环烷基；Z为单取代或双取代的氨基、卤素、烷基、取代烷基、羟基、醚化或酯化的羟基、硝基、氰基、酯化的羧基、烷酰基、氨基甲酰基、N-单取代或N,N-双取代的氨基甲酰基、胍基、胍二氨基基、巯基、磺基、苯硫基、苯较低烷基硫基、烷基苯硫基、苯磺基、苯较低烷基磺基、烷基苯磺基，或（或者，根据该发明的更广泛方面，此外）从尿素基、卤代较低烷硫基、卤代较低烷磺基、吡唑基、较低烷基吡唑基和C2-C7烯基中选择；其中——如果存在多于1个基Z（m≥2），那么取代基Z彼此独立选择；在亚式I*中由波浪线表示的键要么是单键，要么是双键；或者是所述化合物的N-氧化物，其中1个或多个N原子携带氧原子；或其药学上可接受的盐；以及新的邻苯二氮䓬基衍生物；其制备方法；在用于治疗人体或动物体的方法中的应用；用于治疗疾病的用途，特别是由眼部新生血管形成引起的疾病，如老年性黄斑变性或糖尿病性视网膜病变，或对酪氨酸激酶抑制有反应的其他疾病，如增生性疾病；哺乳动物中治疗此类疾病的方法；以及用这种化合物制备药物制剂，特别是用于治疗上述疾病的制剂。
• Phthalazine derivatives with angiogenesis inhibiting activity
  申请人：——

  公开号：US20040180899A1

  公开（公告）日：2004-09-16

  The invention relates to new phthalazine derivatives of formula (I), wherein R 1 and R 2 : a) are independently in each case a lower alkyl; b) together form a bridge of subformula (I*), wherein the bond is achieved via the two terminal C atoms and m is 0 to 4; or c) together form a bridge of subformula (I**), wherein one or two of the ring members T 1 , T 2 , T 3 and T 4 are nitrogen, and the others are in each case CH, and the bond is achieved via atoms T 1 and T 4 ; A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more than three of these radicals are N; X is imino, oxa, or thia; Y is hydrogen, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or unsubstituted or substituted cycloalkyl; and wherein the bonds characterized in subformula (I*) by a wavy line are either single or double bonds; to an N-oxide of a compound of formula I; a tautomer or mixture of tautomers of a compound of formula (I) of an N-oxide thereof; and a pharmaceutically acceptable salt of a compound of formula (I), of an N-oxide or of a tautomer or mixture of tautomers thereof; processes for their preparation and pharmaceutical uses. 1

  本发明涉及公式（I）的新的邻二氮杂菲衍生物，其中R1和R2：a）各自独立地为较低的烷基；b）共同形成子公式（I *）的桥梁，其中通过两个末端C原子实现键合，并且m为0到4；或c）共同形成子公式（I **）的桥梁，其中环成员T1、T2、T3和T4中的一个或两个是氮，其余的分别为CH，并且通过原子T1和T4实现键合；A、B、D、E和T各自独立地为N或CH，但至少一个且不超过三个基团为N；X为亚胺基、氧杂基或硫杂基；Y为氢、取代或未取代的芳基、取代或未取代的杂芳基、或未取代或取代的环烷基；在子公式（I *）中由波浪线表示的键可以是单键或双键；以及公式（I）化合物的N-氧化物，公式（I）化合物的互变异构体或其N-氧化物的混合物；以及公式（I）化合物的药学上可接受的盐，其N-氧化物或其互变异构体或其混合物的制备方法和药物用途。
• Method for producing 4-(heteroaryl-methyl)-halogen-1(2h)-phthalazinones
  申请人：——

  公开号：US20040192695A1

  公开（公告）日：2004-09-30

  A process for the production of 4-(heteroaryl-methyl)-halogen-1(2H)-phthalazinones, especially 4-(4-pyridylmethyl)-1(2H)-phthalazinone, is described, which is characterized by the reaction of phthalidyl-3-triphenylphosphonium salt with 4-pyridine aldehyde in the presence of a basic adjuvant, subsequent reaction with hydrazine hydrate and subsequent acid treatment, whereby this process avoids the technical safety and environmental problems of the known processes.

  本文介绍了一种生产4-(杂环芳基甲基)-卤代-1(2H)-邻菲嗪酮，特别是4-(4-吡啶甲基)-1(2H)-邻菲嗪酮的方法，其特点在于在碱性助剂的存在下，将邻苯二甲酸酐-3-三苯基膦盐与4-吡啶醛反应，随后与水合肼反应并进行酸处理，从而避免了已知方法中存在的技术安全和环境问题。
• Phthalazine Derivatives with Angiogenesis Inhibiting Activity
  申请人：Bold Guido

  公开号：US20090076003A1

  公开（公告）日：2009-03-19

  The invention relates to new phthalazine derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof alone or in combination with one or more other pharmaceutically active compounds for the treatment of a disease, especially of a disease that responds to the inhibition of tyrosine kinases, more especially the inhibition of the vascular endothelial growth factor (VEGF) receptor kinase, preferably the treatment of a proliferative disease, such as a tumour disease.

  本发明涉及新的邻苯二酸咪唑衍生物，其制备方法，其在人或动物体内治疗过程中的应用，其单独或与一种或多种其他药物活性化合物结合使用治疗疾病，特别是对酪氨酸激酶抑制的反应疾病，更特别是对血管内皮生长因子（VEGF）受体激酶抑制的反应疾病，优选是治疗增殖性疾病，如肿瘤疾病的治疗。
• PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES
  申请人：Novartis AG

  公开号：EP1165085B1

  公开（公告）日：2006-06-14